Advanced search
Publication Cover
Clinical Research and Regulatory Affairs Volume 27, 2010 - Issue 1
Journal homepage
57
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Development and application of a validated stability-indicating Ultra-Performance Liquid Chromatography (UPLC) method for the determination of dantrolene and its related impurities

Mobin A. TawakkulDivision of Product Quality Research, Office of Pharmaceutical Science, Food and Drug Administration, Life Science Building 64, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
,
Patrick J. FaustinoDivision of Product Quality Research, Office of Pharmaceutical Science, Food and Drug Administration, Life Science Building 64, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
,
Vilayat A. SayeedDivision of Chemistry 3, Office of Generic Drugs, Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, USA
,
Mansoor A. KhanDivision of Product Quality Research, Office of Pharmaceutical Science, Food and Drug Administration, Life Science Building 64, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
&
Saeed R. KhanDivision of Product Quality Research, Office of Pharmaceutical Science, Food and Drug Administration, Life Science Building 64, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USACorrespondence[email protected]
Pages 21-29 | Received 20 Oct 2009, Accepted 12 Jan 2010, Published online: 18 Feb 2010

References

  • Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene—a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364–373.
  • Snyder HR, Jr Davis, CS, Bickerton RK, Halliday RP. 1-[(5-arylfurfurylidene)amino]hydantoins. A new class of muscle relaxants. J Med Chem 1967;10:807–810.
  • Ellis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JE, Halliday RP. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci 1973;62:948–951.
  • Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975;47:62–65.
  • Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56:254–262.
  • Sudo RT, Carmo PL, Trachez MM, Zapata-Sudo G. Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle. Basic Clin Pharmacol Toxicol 2008;102:308–316.
  • Cox PL, Heotis JP, Polin D, Rose GM. Quantitative determination of dantrolene sodium and its metabolites by differential pulse polarography. J Pharm Sci 1969;58:987–989.
  • Hollifield RD, Conklin JD. Determination of dantrolene in biological specimens containing drug-related metabolites. J Pharm Sci 1973;62:271–274.
  • Conklin JD, Sobers RJ. Qualitative method for dantrolene and a related metabolite in urine. J Pharm Sci 1973;62:1024–1025.
  • Lietman PS, Haslam RH, Walcher JR. Pharmacology of dantrolene sodium in children. Arch Phys Med Rehabil 1974;55:388–392.
  • Ellis KO, Wessels FL. Muscle relaxant properties of the identified metabolites of dantrolene. Naunyn Schmiedebergs Arch Pharmacol 1978;301:237–240.
  • Meyler WJ, Mols-Thurkow HW, Wesseling H. Relationship between plasma concentration and effect of dantrolene sodium in man. Eur J Clin Pharmacol 1979;16:203–209.
  • Meyler WJ, Mols-Thurkow I, Scaf AH, Sargo S, Wesseling H. The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration. Eur J Pharmacol 1979;53:335–342.
  • Hollifield RD, Conklin JD. A spectrophotofluorometric procedure for the determination of dantrolene in blood and urine. Arch Int Pharmacodyn Ther 1968;174:333–341.
  • Saxena SJ, Honigberg IL, Stewart JT, Keene GR, Vallner JJ. Liquid chromatography in pharmaceutical analysis VI: determination of dantrolene sodium in a dosage form. J Pharm Sci 1977;66:286–288.
  • United States Pharmacopeia (USP) 32-NF 27. Monograph for Dantrolene. 32;327.
  • Wren SA, Tchelitcheff P. Use of ultra-performance liquid chromatography in pharmaceutical development. J Chromatogr A 2006;1119:140–146.
  • Novakova L, Matysova L, Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006;68:908–918.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.